Wells Fargo’s Damora Therapeutics, Inc. Ordinary Shares DMRA Stock Holding History

Wells Fargo’s Portfolio DMRA Stock Details DMRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-6	Closed	-$121	–	7112
2024 Q1	$121	Hold	6	–	–	﹤0.01%	6609
2023 Q4	$109	Sell	6 -13	-68%	-$200	﹤0.01%	6747
2023 Q3	$341	Sell	19 -81	-81%	-$3.18K	﹤0.01%	6443
2023 Q2	$6.31K	Hold	100	–	–	﹤0.01%	6036
2023 Q1	$4.97K	Hold	100	–	–	﹤0.01%	6057
2022 Q4	$2.87K	Sell	100 -20	-17%	-$830	﹤0.01%	5917
2022 Q3	$5K	Buy	120 +1	+0.8%	+$51	﹤0.01%	5900
2022 Q2	$5K	Hold	119	–	–	﹤0.01%	6003
2022 Q1	$6K	Hold	119	–	–	﹤0.01%	6419
2021 Q4	$9K	Sell	119 -287	-71%	-$22.5K	﹤0.01%	6577
2021 Q3	$36K	Sell	406 -1,396	-77%	-$149K	﹤0.01%	5746
2021 Q2	$228K	Buy	1,802 +1,800	+90,000%	+$245K	﹤0.01%	4971
2021 Q1	$0	Buy	+2	New	+$544	﹤0.01%	7048

Other funds holding DMRA

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Wells Fargo's DMRA Position: Q2 2024 in Review

Wells Fargo sold out of Damora Therapeutics, Inc. Ordinary Shares (DMRA) in Q2 2024, closing a stake of 6 shares — an estimated $121 sold.

Wells Fargo first reported a position in DMRA in Q1 2021 and held it in 13 quarters. The position peaked at $228K in Q2 2021. 22 funds tracked by Wall St. Rank hold DMRA as of Q2 2024.

Wells Fargo reported no remaining Damora Therapeutics, Inc. Ordinary Shares position as of Q2 2024 after selling out during the quarter.
Wells Fargo sold 6 Damora Therapeutics, Inc. Ordinary Shares shares in Q2 2024, an estimated $121.
Wells Fargo first reported a position in Damora Therapeutics, Inc. Ordinary Shares in Q1 2021 and held it in 13 quarters.
Wells Fargo's Damora Therapeutics, Inc. Ordinary Shares position peaked at $228K in Q2 2021.
22 funds tracked by Wall St. Rank held Damora Therapeutics, Inc. Ordinary Shares as of Q2 2024.

Based on Wells Fargo's 13F filing for Q2 2024, filed 13 Aug 2024.